J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data
Tweet Send to a Friend
J.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
